Summary
- Profile Type
- Business Offer
- POD Reference
- BOFR20230327031
- Term of Validity
- 26 May 2023 - 25 May 2025
- Company's Country
- France
- Type of partnership
- Commercial agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A French SME develops and produces in vitro rapid tests. It has hence specifically developed a rapid test dedicated to diagnosis and personalised therapy/remote follow-up of acute heart failure (HF). Seeked partners are entities willing to purchase or distribute tests on HF.
- Full Description
-
Heart failure (HF) is known to be a major public health problem and a major cause of mortality and morbidity. It has a prevalence of up to 22% in elderly. Aging of population worldwide will result in a further rise in the HF prevalence by 50% over the next 10-15 years. In general practice and in emergency department, HF is a common clinical syndrome characterized by dyspnea, fatigue, and signs of volume overload, which may include peripheral edema and pulmonary rales. There is no single diagnostic test for HF; therefore, it remains a clinical diagnosis requiring a history, physical examination, and laboratory testing. HF diagnosis often requires chest X-ray or echocardiography which remain expensive and not always available in an emergency set-up. However, appropriate diagnosis and early therapy initiation are important given the poor prognosis and to avoid intensive care medicine admission. Survival is 89 percent at one month from diagnosis, 78 percent at one year, and only 57 percent at five years.
Currently, the most frequent laboratory test in Western countries with laboratory access is the determination of brain natriuretic peptides (BNP). It has been demonstrated that diagnosis and therapy guidance using BNP is feasible in the clinical scenario. The use of BNP in the setting of acute dyspnea, a leading hallmark symptom in the emergency department, has been proven. However, natriuretic peptides suffer specificity limitations as biomarkers in this scenario, e.g. a broad “grey zone“ without diagnostic meaning.
Once diagnose with HF, patients remain with chronic HF (CHF) for the rest of their lives and are sent back to home with a prescription based on statistical evidences from clinical studies. This situation “one size fit all” may explain why CHF have frequent rehospitalization rates for HF and a poor prognosis. The diabetics patients were in a similar situation with a high morbidity and comorbidities a few decades ago when they could not check their blood level frequently i.e. at home.
Therefore, the French SME has developed a rapid test for a newly discovered and patented biomarker that allows for:
1) 10 minutes diagnostic of HF without any equipment to complement or replace BNPs. The new biomarker was shown to be more efficient than BNP or NT-proBNP especially in their “grey zone” of values.
2) A combination of rapid test/connected reader for accurate and remote/home HF follow-up of patients (using plasma or a drop of blood) and a secured WEB based interface solution.
The SME seeks:
-Distributors for the SME patented products. Indeed, the SME is focused in R&D and mass production because of the automatization of its production in France.
-Clinics and hospital willing to purchase and use rapids tests. - Advantages and Innovations
-
The SME based in France has over 20 years of background in R & D. Its founder recently reported that in patients presenting with acute dyspnea, the new and patented biomarker displayed greater diagnostic accuracy, especially in the B-type natriuretic peptides “grey zone”
- First, in patients with suspected acute HF presenting to the emergency department, the SME novel biomarker guides decision making by offering a novel option for more rapid diagnosis, hence improving time to appropriate treatment, potentially improving HF outcomes analogue to the “time is muscle” paradigm in acute myocardial infarction. This situation should lead to a lower cost to the healthcare system.
- Second, treatment monitoring in acute and chronic HF will benefit from this new prognostic biomarker, allowing a more precise medicine, e.g. guiding titration of medication or more targeted use of non-pharmacologic options.
Technology benefits: This new rapid biomarker test in the field of HF will help in HF diagnostic and prognostic and in the future could be used for guided therapies.
The expected economical benefits of the SME solution are:
Early detection of HF will lead to a better outcome. Therefore, will reduce the length of decompensated HF and subsequent burden to families and the medical care system cost. Fast detection of HF in acute situation was shown to improve the prognosis of the patients and to lower the cost to the medical care system.
HF is a heavy burden to healthcare systems. HF cost is averaged at ~18 K€/year per patient in Europe, ~80% due to decompensation/rehospitalization cycles. The SME innovation is cost effective and will lower the overall cost of HF by a faster diagnostic and a better follow-up of the patients.
Finally, the SME’s rapid test :
- Has no competitor to date because it is the only test that can make diagnostic without a reader (qualitative set-up for diagnostic);
- Is as simple as the glucose test for the diabetics and will be used by all - Stage of Development
- Already on the market
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- Goal 9: Industry, Innovation and Infrastructure
- IPR status
- IPR granted
Partner Sought
- Expected Role of a Partner
-
The SME is looking for different kinds of partners:
1) European distributors in the field of healthcare products, more precisely diagnostic. The distributor should have a commercial network for the SME products. The distributor(s) will propose to hospitals, general practice MDs and nurses the SME products.
2) Clinics and hospital willing to purchase and promote the SME products
3) Pharmaceutical companies in the field of new drug development looking for new heart failure biomarkers to assess the therapy efficiency. The SME can provide to the partner rapid tests and readers to assure a constant and/or remote monitoring of the new drug therapeutical effect. - Type and Size of Partner
- Other
- SME <=10
- SME 11-49
- Big company
- SME 50 - 249
- Type of partnership
- Commercial agreement
Dissemination
- Technology keywords
- 06001005 - Diagnostics, Diagnosis
- 06001011 - Heart and blood circulation illnesses
- 06002007 - In vitro Testing, Trials
- Market keywords
- 05005010 - Cardiology
- 005001008 - Diagnostic test products and equipment
- 05005013 - Emergency medicine
- 04009 - In vitro Testing, Trials
- Sector Groups Involved
- Health
- Targeted countries
- All countries